Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs10069690
rs10069690
TERT
0.020 GeneticVariation BEFREE hTERT gene polymorphism at rs10069690C/T is associated with the risk and prognosis of thyroid cancer, but hTERT gene polymorphism at rs2736100G/T is not. 27472887

2016
dbSNP: rs10069690
rs10069690
TERT
0.020 GeneticVariation BEFREE A previous genome-wide association study showed that hTERT rs10069690 and rs2736100 polymorphisms were associated with thyroid cancer risk. 31538903

2019
dbSNP: rs1031583860
rs1031583860
GLYAT
0.010 GeneticVariation BEFREE XRCC1 Arg280His and Arg194Trp were associated with thyroid cancer in Pakistani population. 29552790

2019
dbSNP: rs1032006770
rs1032006770
EGFR
0.010 GeneticVariation BEFREE Among them, the MET p.N375S and MLH1 p.V384D mutations, each was detected in two cases, and has rarely been found to be involved in thyroid cancer pathogenesis before. 28757314

2018
dbSNP: rs1042522
rs1042522
TP53
0.020 GeneticVariation BEFREE However, there was no significant association between p53 Arg72Pro po</span>lymorphism and thyroid cancer</span> risk under the other three genetic models (Pro vs. Arg: OR = 1.20, 95% CI 0.87-1.67, P = 0.262; ProPro vs. ArgArg: OR = 1.75, 95% CI 0.88-3.50, P = 0.113; ProPro/ArgPro vs. ArgArg: OR = 1.01, 95% CI 0.66-1.55, P = 0.968). 24037912

2014
dbSNP: rs1042522
rs1042522
TP53
0.020 GeneticVariation BEFREE It is evident from our study that Arg72Pro SNP of TP53 gene is connected with higher susceptibility to thyroid cancer especially in young age group, female gender, non-smokers and patients with elevated TSH levels, hence, implicated in thyroid carcinogenesis. 25835179

2015
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
A 0.710 CausalMutation CLINVAR Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. 23406027

2013
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
G 0.710 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
G 0.710 CausalMutation CLINVAR Phase II trial of sorafenib in metastatic thyroid cancer. 19255327

2009
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
A 0.710 CausalMutation CLINVAR Phase II trial of sorafenib in metastatic thyroid cancer. 19255327

2009
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
G 0.710 CausalMutation CLINVAR Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. 23406027

2013
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
G 0.710 CausalMutation CLINVAR Hyperactive Ras in developmental disorders and cancer. 17384584

2007
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
G 0.710 CausalMutation CLINVAR Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 19773371

2009
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
A 0.710 CausalMutation CLINVAR Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 19773371

2009
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
0.710 GeneticVariation BEFREE Here, we show that depletion of RAF-1, a RAF family member with a poorly defined role in TC, decreases proliferation and increases apoptosis in TPC-1 cells and, less significantly, in cells harboring a BRAF(V600E) or HRAS(G13R) mutations, but without affecting ERK activation. 26265449

2015
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
A 0.710 CausalMutation CLINVAR Hyperactive Ras in developmental disorders and cancer. 17384584

2007
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
A 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
G 0.700 CausalMutation CLINVAR Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. 23406027

2013
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
T 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
G 0.700 CausalMutation CLINVAR Phase II trial of sorafenib in metastatic thyroid cancer. 19255327

2009
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
G 0.700 CausalMutation CLINVAR Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 19773371

2009
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
G 0.700 CausalMutation CLINVAR Hyperactive Ras in developmental disorders and cancer. 17384584

2007
dbSNP: rs104894230
rs104894230
HRAS ; LRRC56
A 0.700 CausalMutation CLINVAR Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. 23406027

2013
dbSNP: rs104894230
rs104894230
HRAS ; LRRC56
A 0.700 CausalMutation CLINVAR Hyperactive Ras in developmental disorders and cancer. 17384584

2007
dbSNP: rs104894230
rs104894230
HRAS ; LRRC56
A 0.700 CausalMutation CLINVAR Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 19773371

2009